Stecher Chad, Ghai Ishita, Lunkuse Lillian, Wabukala Peter, Odiit Mary, Nakanwagi Agnes, Linnemayr Sebastian
College of Health Solutions, Arizona State University, Phoenix, AZ, United States.
Pardee RAND Graduate School, Santa Monica, CA, United States.
JMIR Res Protoc. 2022 Oct 31;11(10):e42216. doi: 10.2196/42216.
Nonadherence to antiretroviral therapy (ART) among people living with HIV is a crucial barrier to attaining viral suppression globally. Existing behavioral interventions have successfully increased ART adherence, but typically show only short-term impact that dissipates after the interventions are withdrawn.
This study aims to test the feasibility, acceptability, and preliminary efficacy of a novel intervention that uses SMS text messages and conditional incentives to support ART initiators in establishing pill-taking habits.
A sample of 150 participants aged ≥18 years who have initiated ART in the preceding 3 months will be recruited from Mildmay Uganda in Kampala, Uganda. All (150/150, 100%) participants will be educated on the anchoring strategy and will choose an existing routine to pair with their daily ART adherence from a set of 3 suggested routines: getting dressed in the morning, eating breakfast, or eating dinner. Then, participants will be randomized to receive either usual care (control group: 50/150, 33.3%) or 1 of the 2 interventions delivered over 3 months: daily SMS text message reminders to follow their chosen anchoring plan (messages group; treatment group 1: 50/150, 33.3%) or daily SMS text messages and incentives conditional on taking their ART medication around the time of their chosen anchor (incentives group; treatment group 2: 50/150, 33.3%). Long-term ART adherence will be evaluated for 6 months after the intervention, and survey assessments will be conducted at baseline, 3 months, and 9 months. Outcomes include feasibility and acceptability measures and intervention efficacy outcomes defined by electronically measured mean medication adherence during the intervention and during the 6 months after the intervention, along with a measure of routine ART adherence based on taking medications around the time of participants' anchor during the intervention and during the 6 months after intervention.
As of February 18, 2022, recruitment was completed. A total of 150 participants were recruited, and data collection is expected to end in December of 2022. Final results are expected to be submitted for publication by April 2023.
This study is the first to use behavioral economics-based interventions in combination with the anchoring strategy to improve long-term ART adherence among treatment initiators. We hypothesize that the combination of SMS text message reminders and incentives will increase participants' use of their anchoring strategy, and thus medication adherence will be better maintained after the intervention ends in our intervention groups relative to the control group that uses only the anchoring strategy. Results of this pilot study will help to refine this combined intervention approach for testing at scale and broaden our understanding of the habit formation process.
ClinicalTrials.gov NCT05131165; https://clinicaltrials.gov/ct2/show/NCT05131165.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/42216.
艾滋病毒感染者对抗逆转录病毒疗法(ART)的不依从是全球实现病毒抑制的关键障碍。现有的行为干预措施已成功提高了ART依从性,但通常仅显示短期效果,在干预措施撤销后效果就会消失。
本研究旨在测试一种新型干预措施的可行性、可接受性和初步疗效,该干预措施使用短信和有条件激励措施来帮助ART初治者养成服药习惯。
将从乌干达坎帕拉的米尔德梅乌干达医院招募150名年龄≥18岁且在过去3个月内开始接受ART治疗的参与者。所有(150/150,100%)参与者都将接受锚定策略教育,并将从3种建议的日常活动中选择一种现有的日常活动与他们的每日ART依从性配对:早上穿衣、吃早餐或吃晚餐。然后,参与者将被随机分配接受常规护理(对照组:50/150,33.3%)或在3个月内实施的2种干预措施中的一种:每日短信提醒以遵循他们选择的锚定计划(短信组;治疗组1:50/150,33.3%)或每日短信以及根据在其选择的锚定时间附近服用ART药物给予激励(激励组;治疗组2:50/150,33.3%)。将在干预后6个月评估长期ART依从性,并在基线、3个月和9个月进行调查评估。结果包括可行性和可接受性指标,以及通过电子测量的干预期间和干预后6个月的平均药物依从性定义的干预疗效指标,以及基于干预期间和干预后6个月在参与者锚定时间附近服药情况的常规ART依从性指标。
截至2022年2月18日,招募工作已完成。共招募了150名参与者,数据收集预计于2022年12月结束。最终结果预计将于2023年4月提交发表。
本研究首次将基于行为经济学的干预措施与锚定策略相结合,以提高治疗初治者的长期ART依从性。我们假设短信提醒和激励措施的结合将增加参与者对锚定策略的使用,因此相对于仅使用锚定策略的对照组,我们干预组在干预结束后药物依从性将得到更好的维持。这项试点研究的结果将有助于完善这种联合干预方法以便进行大规模测试,并拓宽我们对习惯形成过程的理解。
ClinicalTrials.gov NCT05131165;https://clinicaltrials.gov/ct2/show/NCT05131165。
国际注册报告识别码(IRRID):DERR1-10.2196/42216。